Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume 31, Issue 4, Pages 643-649Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-011-9525-7
Keywords
Indoleamine 2,3-dioxygenase; tryptophanyl-tRNA synthetase; immune thrombocytopenic purpura
Categories
Funding
- National Natural Science Foundation of China [81070408, 81070411, 30570779, 30770922, 81070407, 30971278, 81070396]
- National 973 Basic Research Program of China [2011CB503906]
- Foundation for the Author of National Excellent Doctoral Dissertation of PR China [200561]
- Program for New Century Excellent Talents in University [NCET-07-0514]
- Chinese Ministry of Education [109097]
- Public Health Ministry of China
- Outstanding Young Scientist Research Award Foundation of Shandong Province [2008BSO3009, BS2010YY024]
- Natural Science Foundation of Shandong Province [ZR2009CM001, ZR2010HQ002]
- Clinical Medicine Center Foundation of Shandong Province
- Leading Medical Professionals Foundation of Shandong Province
- Tai Shan Scholar Foundation
- Independent Innovation Foundation of Shandong University [2009TS053]
- National Natural Science Foundation of China for Innovative Research Group [81021001]
Ask authors/readers for more resources
Indoleamine 2,3-dioxygenase (IDO) can promote peripheral immune tolerance and control autoimmune responses through tryptophan catabolism. Tryptophanyl-tRNA synthetase (TTS) can protect T cells from IDO-mediated cell injury. Impaired IDO-mediated tryptophan catabolism has been observed in some autoimmune diseases. The concentrations of plasma kynurenine and tryptophan were detected by high-pressure liquid chromatography. The expressions of IDO and TTS were analyzed by real-time quantitative polymerase chain reaction and flow cytometry. Compared with healthy controls, the PBMCs of patients with immune thrombocytopenia (ITP) had significantly increased expressions of IDO and TTS, especially IDO. However, the plasma tryptophan concentration was significantly elevated, and kynurenine concentration was significantly reduced in ITP patients. In CD4(+) and CD8(+) T cells of the ITP patients, IDO expressions were significantly lower than those in healthy controls, but in CD19(+) and CD14(+) cells, IDO expression significantly increased. Conversely, TTS expressions in CD4(+) and CD8(+) T cells of the ITP patients were significantly higher than those in healthy controls, but there was no difference either in CD19(+) or CD14(+) cells. These results suggest that the activity of IDO enzyme is insufficient in ITP patients. Increased TTS expressions from CD4(+) and CD8(+) T cells might link to a pathogenic mechanism involved in increasing survival of autoreactive T cells in ITP patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available